Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers - PubMed (original) (raw)

Review

Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers

Shruti Chaturvedi et al. Curr Rheumatol Rep. 2017 Jul.

Abstract

Purpose of review: Laboratory criteria for the classification of antiphospholipid syndrome include the detection of a lupus anticoagulant and/or anticardiolipin and anti-β2-glycoprotein I antibodies. However, the majority of patients who test positive in these assays do not have thrombosis. Current risk-stratification tools are largely limited to the antiphospholipid antibody profile and traditional thrombotic risk factors.

Recent findings: Novel biomarkers that correlate with disease activity and potentially provide insight into future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other phospholipids or phospholipid/protein antigens (such as anti-PS/PT), and functional/biological assays such as thrombin generation, complement activation, levels of circulating microparticles, and annexin A5 resistance. Clinical risk scores may also have value in predicting clinical events. Biomarkers that predict thrombosis risk in patients with antiphospholipid antibodies have been long sought, and several biomarkers have been proposed. Ultimately, integration of biomarkers with established assays and clinical characteristics may offer the best chance of identifying patients at highest risk of APS-related complications.

Keywords: Antiphospholipid antibodies; Biomarker; Complement; Lupus anticoagulant; Thrombosis; β-2-Glycoprotein-I.

PubMed Disclaimer

Similar articles

• Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
  Iwaniec T, Kaczor MP, Celińska-Löwenhoff M, Polański S, Musiał J. Iwaniec T, et al. Thromb Res. 2017 May;153:90-94. doi: 10.1016/j.thromres.2017.02.019. Epub 2017 Feb 24. Thromb Res. 2017. PMID: 28363116
• Antiphospholipid antibodies: evaluation of the thrombotic risk.
  Devreese KM. Devreese KM. Thromb Res. 2012 Oct;130 Suppl 1:S37-40. doi: 10.1016/j.thromres.2012.08.270. Thromb Res. 2012. PMID: 23026657 Review.
• [Antiphospholipid antibodies in practice].
  Miyara M, Diemert MC, Amoura Z, Musset L. Miyara M, et al. Rev Med Interne. 2012 Apr;33(4):176-80. doi: 10.1016/j.revmed.2011.09.018. Epub 2011 Nov 17. Rev Med Interne. 2012. PMID: 22100197 French.
• Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review.
  Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Sciascia S, et al. Thromb Haemost. 2014 Feb;111(2):354-64. doi: 10.1160/TH13-06-0509. Epub 2013 Oct 31. Thromb Haemost. 2014. PMID: 24172938 Review.
• [Pathogenesis and Laboratory Findings in Antiphospholipid Syndrome, Especially Associated with Lupus Anticoagulant].
  Ieko M, Naito S, Yoshida M, Takahashi N. Ieko M, et al. Rinsho Byori. 2015 Oct;63(10):1220-7. Rinsho Byori. 2015. PMID: 26897860 Review. Japanese.

Cited by

• Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives.
  Foret T, Dufrost V, Lagrange J, Costa P, Mourey G, Lecompte T, Magy-Bertrand N, Regnault V, Zuily S, Wahl D. Foret T, et al. Curr Rheumatol Rep. 2024 May;26(5):178-187. doi: 10.1007/s11926-024-01140-1. Epub 2024 Feb 19. Curr Rheumatol Rep. 2024. PMID: 38372872 Review.
• Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review.
  Hermel M, Hermel D, Azam S, Shinbane J, Sarcon A, Jones E, Mehta A, Grazette L, Liebman H, Weitz I. Hermel M, et al. EJHaem. 2020 Jul 31;1(1):44-50. doi: 10.1002/jha2.71. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847716 Free PMC article.
• Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.
  Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, Gavriilaki E, Alluri R, Streiff MB, Petri M, Crowther MA, McCrae KR, Brodsky RA. Chaturvedi S, et al. Blood. 2020 Jan 23;135(4):239-251. doi: 10.1182/blood.2019003863. Blood. 2020. PMID: 31812994 Free PMC article.
• Osteopontin as a biomarker for osteosarcoma therapy and prognosis.
  Han X, Wang W, He J, Jiang L, Li X. Han X, et al. Oncol Lett. 2019 Mar;17(3):2592-2598. doi: 10.3892/ol.2019.9905. Epub 2019 Jan 8. Oncol Lett. 2019. PMID: 30854034 Free PMC article. Review.
• New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats.
  Durigutto P, Grossi C, Borghi MO, Macor P, Pregnolato F, Raschi E, Myers MP, de Groot PG, Meroni PL, Tedesco F. Durigutto P, et al. Haematologica. 2019 Apr;104(4):819-826. doi: 10.3324/haematol.2018.198119. Epub 2018 Nov 15. Haematologica. 2019. PMID: 30442725 Free PMC article.

References

1. 1. Clin Chem. 2001 Jun;47(6):1008-15 - PubMed
2. 1. Br J Rheumatol. 1998 Oct;37(10):1089-94 - PubMed
3. 1. Blood. 1989 Nov 15;74(7):2426-32 - PubMed
4. 1. Clin Chem Lab Med. 2014 Sep;52(9):1329-33 - PubMed
5. 1. Thromb Res. 2010 Aug;126(2):150-3 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal